Geron Corporation
GERNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeGeron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. With a market capitalization of $1.01B, it sits in small-cap territory. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Market Cap
$1.01B
Beta
0.60
P/E (TTM)
—
P/E (Fwd)
39.25
EPS (TTM)
$-0.11
EPS (Fwd)
$0.04
ROE
-28.3%
ROA
-4.1%
Cash
$300.8M
Total Debt
$122.1M
Free CF
-$78.4M
52W Change
15.4%
Annual Financials
Cash vs Debt
Where GERN stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, GERN finished 0.68% above its 150-day moving average ($1.48) and 4.20% above its 200-day moving average ($1.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GERN overbought or oversold?
At the September 1, 2026 close, GERN's RSI(14) was 34.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $300.8M in cash and $122.1M in debt, GERN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$78.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -28.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $596K (2022) to $183.9M (2025), reflecting a 30753% increase over the period.
GERN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GERN.